You are here
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
A Novel Therapeutic that Harnesses Microtubules to Promote Cavernous Nerve Regeneration after Radical ProstatectomySBC: MICROCURES INC Topic: 300
Radical prostatectomy (RP) is a commonly used treatment option for localized prostate cancer, which carries a high risk for development of erectile dysfunction (ED) because of cavernous nerve (CN) injury. Even newer, nerve-sparing, robotic procedures do not convincingly improve erectile function (EF) outcomes after RP. In addition, ED resulting from RP is often refractory to treatment by orally ad ...STTR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health
SBC: KLEIN BUENDEL, INC. Topic: NICHD
Internet-based TRAC (i-TRAC): Interactive Emotion Regulation Skills Training to Improve AdolescentSexual Health Adolescence is a critical developmental period during which behavioral patterns are formed that have powerful influences on current and future health. This is particularly true for sexual behavior, which is affected by the biological changes of puberty as well as normative developmental ...STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
SBC: PACDNA LLC Topic: NCI
Project Summary/AbstractMutant forms of KRAS are a key driver in human tumors but remain partially refractory to therapeutic intervention. After over three decades of research, only a single inhibitor (sotorasib) targeting a single mutation (KRASG12C) have reached market. The difficulty for developing small molecule KRAS inhibitors has heightened the importance of alternative methods targeting the ...STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
SBC: HOPEFUL AGING LLC Topic: NIA
PROJECT SUMMARY/ABSTRACTHealthcare systems around the world, including within the United States, have long-established shortages of trained caregivers (WHO, 2016; Jones, Liu, Murfield, andamp; Moyle, 2020). The American Health Care Association (2019) states that “the health care system has experienced a shortage of trained caregivers for critical roles for some time.” This scarcity directly im ...STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
SBC: GROW BIOMEDICINE LLC Topic: 300
Project Summary We have developed a candidate product that induces colon epithelial repair in ulcerative colitis (UC) models. UC comprises a major type of inflammatory bowel disease and is characterized by chronic and relapsing inflammation in the gastrointestinal (GI) tract. UC develops in the innermost mucosal layer of the distal GI tract in a continuous manner, usually starting at the rectum an ...STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
SBC: BUTO CORPORATION Topic: NIA
Abstract. Alzheimer’s disease (AD) affects more than 5M Americans today, and is the most common cause of dementia in adults. While current medications slightly delay symptoms, no medications exist to cure or stop disease progression. A current focus at NIA is to identify novel drug targets, that address resilience to AD; also, there is an increasing perspective at NIA that Multi-target therapy m ...STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
SBC: NOVORON BIOSCIENCE INC Topic: NIA
7. Project Summary Alzheimer’s disease (AD) is the most common cause of dementia and is a growing problem as populations age. More than 25 million people are affected by dementia worldwide with most suffering from AD. AD is characterized by the presence of plaques of insoluble amyloid-beta (Aβ) and tangles of hyperphosphorylated aggregates of the cytoskeletal protein, tau. Thus far, most AD tre ...STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
Feelix @ Home: Testing and optimization of a smart stethoscope for home use to monitor changes in lung status of individuals with chronic conditionsSBC: SONAVI LABS INC Topic: NHLBI
Project SummaryThe goal of this project is to further develop an existing smart stethoscope in order to be capable of monitoring pediatric patients at home who suffer from asthma as well as adults with COPD. Lung diseases impose a serious burden on healthcare systems, individuals and governments. The World Health Organization (WHO) found that chronic obstructive pulmonary disease (COPD) and lower ...STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
Technology transfer of behavioral economic tasks for assessing alcohol reinforcer pathology: Development and feasibility of a commercially-available tool for clinical practiceSBC: BEAM Diagnostics, Inc. Topic: 270
PROJECT SUMMARY Alcohol use disorder (AUD) contributes to excessive disability, morbidity, and mortality in the United States. As one of the nation’s leading causes of death, public health guidelines recommend consistent standardized alcohol screening. However, screening for alcohol misuse is underperformed, laborious, and is susceptible to demand characteristics and concerns about stigmatizing ...STTR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health
Development of novel, targeted small molecule inhibitors of DNA repair in high unmet need tumors-TNBCSBC: DNATWO, Inc. Topic: NCI
DNATWO, Inc. was founded out of Caltech to develop small molecule drugs targeting a new cancer target, DNA2, to treat triple-negative breast cancer (TNBC). We have spent decades unraveling the role of the DNA2 ATP-motor driven nuclease activity in relieving replication stress at the replication fork and carrying out repair at forks collapsed to double strand breaks (DSBs). Our scientific premise i ...STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health